Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM +0.40%71 Intrinsic Value: Projected FCF is BDT34.48 as of Sep. 21, 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT19.40 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 240 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 51.67% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-21), Orion Pharma's Intrinsic Value: Projected FCF is BDT34.48. The stock price of Orion Pharma is BDT25.10. Therefore, Orion Pharma's Price-to-Intrinsic-Value-Projected-FCF of today is 0.7.
The historical rank and industry rank for Orion Pharma's Intrinsic Value: Projected FCF or its related term are showing as below:
DHA:ORIONPHARM'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.25 Med: 0.93 Max: 1.95
Current: 0.73
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Orion Pharma was 1.95. The lowest was 0.25. And the median was 0.93.
DHA:ORIONPHARM's Price-to-Projected-FCF is ranked better than 51.67% of 240
companies
in the Utilities - Independent Power Producers industry
Industry Median: 0.76
vs DHA:ORIONPHARM: 0.73
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Orion Pharma's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
25.10
/
14.123751041556
=
1.78
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma Intrinsic Value: Projected FCF Related Terms
Orion Pharma Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Intrinsic Value: Projected FCF Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Price-to-Projected-FCF vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of BDT34.48 mean?
Orion Pharma (DHA:ORIONPHARM) has a Intrinsic Value: Projected FCF of BDT34.48 as of Sep. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Orion Pharma and its competitors. According to the industry distribution chart, Orion Pharma ranks #116 out of 240 companies in the Utilities - Independent Power Producers industry, placing it in the top 48.3%.
Is Orion Pharma's Intrinsic Value: Projected FCF too high?
Orion Pharma's current Intrinsic Value: Projected FCF is BDT34.48. Based on the distribution chart, Orion Pharma ranks #116 out of 240 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Intrinsic Value: Projected FCF compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #116 out of 240 companies for Intrinsic Value: Projected FCF. This puts Orion Pharma in the upper half of its industry. The industry median Intrinsic Value: Projected FCF is 0.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for an Utilities - Independent Power Producers company?
The median Intrinsic Value: Projected FCF among Utilities - Independent Power Producers companies is 0.76, based on 240 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Intrinsic Value: Projected FCF is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Intrinsic Value: Projected FCF is BDT34.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.40, compared to a current price of BDT25.10 — trading 29.4% above its estimated fair value. The current Intrinsic Value: Projected FCF is BDT34.48. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Intrinsic Value: Projected FCF is BDT34.48 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT25.10 is trading 29.4% above its estimated GF Value™ of BDT19.40.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Intrinsic Value: Projected FCF: BDT34.48
GF Value™: BDT19.40 vs. price of BDT25.10 (29.4% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
